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ABSTRACT
Background: Obesity is a serious chronic disease. Controlled-release
phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle
modiﬁcation, has previously shown signiﬁcant weight loss com-
pared with placebo in a 56-wk study in overweight and obese sub-
jects with 2 weight-related comorbidities.
Objective: This study evaluated the long-term efﬁcacy and safety of
PHEN/TPM CR in overweight and obese subjects with cardiome-
tabolic disease.
Design: This was a placebo-controlled, double-blind, 52-wk extension
study; volunteers at selected sites continued with original randomly
assigned treatment [placebo, 7.5 mg phentermine/46 mg controlled-
release topiramate (7.5/46), or 15 mg phentermine/92 mg controlled-
release topiramate (15/92)] to complete a total of 108 wk. All
subjects participated in a lifestyle-modiﬁcation program.
Results: Of 866 eligible subjects, 676 (78%) elected to continue in
the extension. Overall, 84.0% of subjects completed the study,
with similar completion rates between treatment groups. At week
108, PHEN/TPM CR was associated with signiﬁcant, sustained
weight loss (intent-to-treat with last observation carried forward;
P , 0.0001 compared with placebo); least-squares mean percent-
age changes from baseline in body weight were –1.8%, –9.3%,
and –10.5% for placebo, 7.5/46, and 15/92, respectively. Signiﬁ-
cantly more PHEN/TPM CR–treated subjects at each dose
achieved 5%, 10%, 15%, and 20% weight loss compared
with placebo (P , 0.001). PHEN/TPM CR improved cardiovas-
cular and metabolic variables and decreased rates of incident di-
abetes in comparison with placebo. PHEN/TPM CR was well
tolerated over 108 wk, with reduced rates of adverse events oc-
curring between weeks 56 and 108 compared with rates between
weeks 0 and 56.
Conclusion: PHEN/TPM CR in conjunction with lifestyle modiﬁca-
tion may provide a well-tolerated and effective option for the sustained
treatment of obesity complicated by cardiometabolic disease. This
trial was registered at clinicaltrials.gov as NCT00796367. Am J
Clin Nutr 2012;95:297–308.
INTRODUCTION
Obesity is a global epidemic (1, 2). This chronic disease
increases morbidity and mortality, in large part due to associated
comorbidities, including T2D
4, CVD, metabolic syndrome, liver
disease, and cancer (1–7). The ﬁrst-line strategy for the treat-
ment of obesity and prevention of cardiometabolic disease is
achieving weight loss through lifestyle interventions, which
consist of reductions in caloric intake (by 500–1000 calories/d),
increases in physical activity, and changes in health behaviors
(8). However, adherence to lifestyle changes can be challenging
for a wide variety of reasons, such as a lack of readiness for
change on the part of the patient, physical restrictions that limit
activity, and a shortage of therapeutic venues that include
a multidisciplinary health care team essential to treatment
effectiveness. When lifestyle changes alone do not provide the
desired weight loss, the addition of pharmacotherapy or bariatric
surgery provides a viable option for patients meeting eligibility
criteria. However, effective pharmacologic options are limited,
and indication for bariatric surgery is limited to patients with
a high BMI due to the inherent risks of invasive procedures (9,
10). Thus, it is imperative that effective, long-term pharmacologic
strategies are identiﬁed that may be used in conjunction with
lifestyle changes to combat the obesity epidemic.
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creaticlipaseinhibitor,istheonlyapprovedagentforthelong-term
pharmacologic treatment of obesity in the United States (10).
Phentermine (Apidex-P; Teva), a central norepinephrine-releasing
drug, is approved for short-term (a few weeks) treatment of
obesity as monotherapy (37.5 mg/d) (10, 11). Topiramate (Topa-
max;Janssen Pharmaceuticals),ananticonvulsant (200–400 mg/d)
that is also approved for the prophylaxis of migraine headaches
(100 mg/d), has shown weight-loss properties but is not currently
approved as a therapy for obesity (10, 12–16). A low-dose
combination of phentermine plus controlled-release topiramate
(PHEN/TPM CR) as an adjunct to lifestyle modiﬁcation was
previously shown to reduce body weight through 56 wk of
treatment in the CONQUER study (17). The SEQUEL study, an
extension of the CONQUER study, was designed to assess the
longer-term efﬁcacy and safety of lifestyle intervention and 2
doses of PHEN/TPM CR for an additional 52 wk (ie, a total
treatment duration of 108 wk).
SUBJECTS AND METHODS
Subjects
All subjects were eligible to enroll in the extension study if
they completed the CONQUER study on treatment and complied
with protocol requirements. Inclusion and exclusion criteria for
CONQUER required subjects to have a BMI (in kg/m
2)o f27
and 45 as well as 2 weight-related comorbidities, as pre-
viously described in detail (17). To continue into the SEQUEL
extension study, female subjects of childbearing potential were
required to continue contraception in the form of a double-
barrier method, stable hormonal contraception plus single bar-
rier, or tubal ligation. Exclusion criteria included having a
BMI 22 at the completion of the CONQUER study, contin-
uously not taking the study drug for .4 wk at the completion
of the CONQUER study, developing a condition during the
CONQUER study that would interfere with compliance or at-
tainment of study measures, or participating in another formal
weight-loss program.
Study design
SEQUEL was a double-blind, placebo-controlled, 52-wk ex-
tension of the CONQUER study. On completion of the 56-wk
CONQUER study (17), sites that met the criteria described below
were eligible to offer enrollment in SEQUEL. Participants in
SEQUEL continued with the original treatment to which they
were randomly assigned during CONQUER: lifestyle interven-
tion plus placebo, lifestyle plus 7.5 mg phentermine/46 mg
controlled-release topiramate, or lifestyle plus 15 mg phenter-
mine/92 mg controlled-release topiramate, hereafter referred to
as placebo, 7.5/46,and 15/92, respectively. Of the 93 CONQUER
sites,36wereselected fortheextension studyon thebasis oftheir
high initial enrollment numbers and rates of retention, and these
sites remained blinded to assigned treatment through the end of
SEQUEL. This study was conducted between December 2008
and June 2010 and was approved by institutional review boards at
each site. All subjects provided written informed consent for
participation in the SEQUEL extension. This trial was registered
with clinicaltrials.gov as NCT00796367.
Randomization and interventions
Subjects were randomly assigned by using a computer-gen-
erated algorithm and were stratiﬁed according to their sex and
diabetic status. Study drugs and placebo were administered as
capsules that were identical in size and appearance. Eligible
subjects maintained their originally assigned once-daily treat-
ment from the CONQUER study (2:1:2 randomization for pla-
cebo, 7.5/46, or 15/92) (17). Investigators and subjects remained
blinded to treatment assignment. The screening visit for the
extension study occurred at the ﬁnal CONQUER visit, and study
visitsoccurredat4-wkintervalsthereafter.Allsubjectscontinued
to receivestandardized diet and lifestyle-modiﬁcation counseling
based on the LEARN (Lifestyle, Exercise, Attitudes, Relationships,
and Nutrition) program (18). Dose reductions or interruptions
were allowed for subjects who experienced AEs or who had
tolerability issues. Subjects discontinuing the study drug were
encouraged to remain in the study, complete study assessments,
and continue with the lifestyle counseling according to the
LEARN program.
Study endpoints
The CONQUER study had 2 predeﬁned, coprimary endpoints,
which were retained as the primary outcome measures in the
SEQUEL extension study: mean percentage weight loss and
percentage of subjects achieving 5% weight loss from baseline
(week 0 of CONQUER) to week 108. Secondary endpoints in-
cluded the following: weight loss in kilograms; percentage of
subjects achieving 10%, 15%, or 20% weight loss; and
change in waist circumference from baseline to week 108. Other
efﬁcacy endpoints included changes from baseline to week 108
in blood pressure, serum lipid variables, glycemic measures,
concomitant medications for weight-related comorbidities, and
rate of progression to diabetes among subjects without diabetes
at baseline. All subjects were assessed for diabetic status at
baseline per the 2007 American Diabetes Association guide-
lines, as follows: fasting blood glucose 126 mg/dL or 2-h
blood glucose 200 mg/dL after an oral-glucose-tolerance test
(19). Hb A1c concentrations were also obtained to assess degree
of hyperglycemia but were not used as a diagnostic criterion for
diabetes at baseline (20). Subjects were considered to have
progressed to T2D if their blood glucose was 126 mg/dL under
fasting conditions during 2 consecutive measurements and/or
200 mg/dL at 2 h after an oral-glucose-tolerance test. Safety
assessments included AEs, physical examination, clinical and
laboratory measurements, vital signs, and electrocardiography.
At each visit, depressive symptoms were assessed by using the
9-item Patient Health Questionnaire self-reported assessment
for depressive symptoms, and the presence of suicidal ideation
or behavior was assessed by using the C-SSRS, an 11-item,
clinician-administered assessment.
Statistical analysis
Analyses of change in weight, waist circumference, and other
continuous efﬁcacy measures were conducted in a modiﬁed ITT
sample with the LOCF method to impute missing values. The
modiﬁed ITT sample was deﬁned as all subjects who received at
least one study drug dose with at least one postbaseline mea-
surement of body weight. ANCOVA was used to evaluate per-
centage weight loss, with treatment, sex, and diabetic status as
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corresponding SEs, 2-sided 95% CIs, and 2-sided P values for
percentage weight loss within each treatment group were de-
rived from the ANCOVA. Analyses of percentage of categorical
weight loss were conducted by using logistic regression, with
treatment, sex, and diabetic status as ﬁxed effects and baseline
weight as a covariate. For each treatment comparison, the esti-
mated OR, SE, 95% Wald CI, and P value were determined.
Multiple imputation was used as a sensitivity analysis to sup-
plement the ITT-LOCF approach, and an analysis of subjects
who completed the study while actively taking the study drug
was also performed to understand the effect of treatment after
108 wk of exposure.
The annualized incidence rate of T2D was calculated as the
number of newly diagnosed subjects divided by the number of
subject-years of follow-up for each treatment group. The number
of subject-years of follow-up was calculated as the sum of the
numberof daysacrossall subjects fromthe randomizationdatein
CONQUER to the onset date of T2D or to the date of completion
or discontinuation from SEQUEL (for subjects who did not
develop T2D) divided by 365.25.
Safety analyses were based on incidence of AEs, changes in
laboratory evaluations, vital signs, electrocardiograms, physical
examination ﬁndings, and results from the 9-item Patient Health
Questionnaire and the C-SSRS during both the CONQUER and
SEQUELstudies.TEAEsweredeﬁnedasAEsoccurringbetween
week 0 of CONQUER and 28 d after the last dose of double-
blind study drug in SEQUEL. Analysis of TEAEs was also
performed from the start date of study drug in the SEQUEL
study and 28 d after the last dose of study drug in the SEQUEL
study. All other safety variables were measured between base-
line (week 0 of CONQUER) and week 108 or early termination.
RESULTS
Disposition of study subjects and baseline characteristics
Of the 866 subjects who completed the CONQUER trial at
eligibleSEQUELsites,676(78.1%)electedtoenrollinSEQUEL
and continue receiving their blinded treatment as an adjunct to
lifestyle modiﬁcation for an additional 52 wk (Figure 1). A
greater proportion of subjects in the 15/92 treatment arm
(85.5%) consented to continue with treatment than did subjects
in the 7.5/46 treatment arm (79.4%), whereas the placebo group
had the lowest proportion of subjects electing to continue in the
protocol (69.4%). Overall, 84.0% (568/676) of subjects com-
pleted the extension study, including 86.3% (196/227) of those
assigned to placebo, 82.5% (127/154) of those assigned to 7.5/
46, and 83.1% (245/295) of those in the 15/92 group. Seven
(3.1%) subjects in the placebo arm, 7 (4.5%) subjects in the 7.5/
46 arm, and 13 (4.4%) in the 15/92 arm, discontinued the study
drug due to an AE (Figure 1). Three subjects in the placebo arm
and one subject in the 7.5/46 arm stopped treatment due to lack
of efﬁcacy, whereas no subjects in the 15/92 arm discontinued
due to lack of efﬁcacy. A higher number of subjects were lost to
follow-up in the 15/92 group (20 subjects) than in either the
placebo or 7.5/46 groups (4 subjects each).
Baseline demographic, anthropometric, and clinical charac-
teristics, including comorbidities, were similar among subjects in
all 3 treatment arms of the SEQUEL study, and in each of the
treatmentarmsthe characteristics ofthesubjects inSEQUEL were
similar to and representative of the larger CONQUER cohort
(Table 1). Whereas the proportion of subjects with hypertension
and dyslipidemia was similar between groups and between
CONQUER and SEQUEL, a greater percentage of subjects en-
rolling in SEQUEL had T2D at baseline compared with the
original CONQUER cohort (21.5% compared with 15.8%, re-
spectively). In total, 451 (66.8%) subjects in SEQUEL met the
American Heart Association and National Heart, Lung, and Blood
Institute criteria (21, 22) for metabolic syndrome at baseline,
including 152 (67.0%) in the placebo group, 107 (69.9%) in the
7.5/46 group, and 192 (65.1%) in the 15/92 group.
Weight loss
Subjects in both PHEN/TPM CR arms showed signiﬁcantly
greater percentage weight loss than did those in the placebo
arm, and the weight loss was sustained during 108 wk (Figure 2;
P , 0.0001 compared with placebo at all time points assessed).
At week 108, the LS mean percentage changes from baseline in
body weight in the ITT-LOCF analysis were signiﬁcantly greater
in the PHEN/TPM CR groups compared with placebo: –1.8%,
–9.3%, and –10.5% for placebo, 7.5/46, and 15/92, respectively
(P , 0.0001 compared with placebo for all comparisons). For
subjects who completed the study while still taking the study
drug at week 108, the LS mean percentage changes from
baseline in body weight were also signiﬁcantly greater in
the PHEN/TPM CR groups compared with placebo: –2.2%,
–9.3%, and –10.7% for placebo, 7.5/46, and 15/92, respectively
(P , 0.0001 compared with placebo for all comparisons).
Absolute LS mean weight loss using ITT-LOCF data were –2.1,
–9.6, and –10.9 kg for the placebo, 7.5/46, and 15/92 groups,
respectively (P , 0.0001 compared with placebo for all com-
parisons). Greater proportions of subjects treated with each dose
of PHEN/TPM CR experienced weight losses of 5%, 10%,
15%, and 20% when compared with placebo-treated subjects
(Figure 3; P , 0.0001 for all comparisons except for weight
loss 20% for the 7.5/46 group, P = 0.0072; ITT-LOCF). There
were also signiﬁcant reductions in waist circumference at Week
108 in subjects treated with PHEN/TPM CR, with mean
reductions of –3.6, –9.8, and –10.6 cm for placebo, 7.5/46, and
15/92 treatment arms, respectively (P , 0.0001 compared with
placebo; ITT-LOCF).
An analysis of weight loss as a function of baseline BMI
category (,30, 30 and ,35, 35 and ,40, 40 and ,45)
was performed (see Supplemental Figure 1 under “Supplemental
data” in the online issue). PHEN/TPM CR was clearly effective
in all BMI categories and produced greater weight loss than did
placebo (P  0.0061). However, a signiﬁcant treatment effect by
baseline BMI category was observed (P = 0.0327). Whereas the
7.5/46 and 15/92 doses were statistically similar in their effec-
tiveness in the lower baseline BMI categories, the 15/92 group
showed signiﬁcantly greater percentage weight loss than did the
7.5/46 group in the most severely obese subjects (baseline
BMI 40 and ,45; P = 0.0016 compared with 7.5/46). Among
all subjects with class II obesity or greater at baseline (ie,
BMI 35) (8), LS mean percentage weight losses at week 108
were signiﬁcantly greater for PHEN/TPM CR compared with
placebo (P , 0.0001; ITT-LOCF): –3.4%, –10.1%, and –12.6%
for placebo, 7.5/46, and 15/92 treatment arms, respectively.
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with T2D at baseline, the PHEN/TPM CR–treated subjects also
showed greater weight loss when compared with placebo-treated
subjects. At week 108, subjects with T2D in the placebo group
(n = 55) lost 2.0% of their body weight, whereas subjects with
T2D in both the 7.5/46 (n = 26) and 15/92 (n = 64) groups
lost 9.0% of their body weight (P = 0.0003 for 7.5/46 and
P , 0.0001 for 15/92 compared with placebo).
Changes in weight-related comorbidities
Consistent with study entry criteria, enrolled subjects were
generally affected by cardiometabolic disease. Many subjects
were receiving medications to control blood pressure, lipid
variables, and glucose concentrations, and all subjects were
actively managed throughout the trial to control these comor-
bidities. Blood pressure in subjects with hypertension was
generally well controlled with 2 antihypertensive medications,
the most common of which were angiotensin-converting enzyme
inhibitors, thiazide diuretics, and selective b-blockers. More
than one-third of subjects with dyslipidemia were receiving
statins; speciﬁcally, 78 (34.4%), 58 (37.9%), and 93 (31.5%)
subjects randomly assigned to the placebo, 7.5/46, and 15/92
subgroups, respectively, were taking statins. The second most
common lipid-controlling treatment was ﬁsh oil or a speciﬁc
omega-3 formulation. Subjects with diabetes (n = 145) were
required to be managed with a regimen of diet and exercise or
metformin monotherapy; 38 (69.1%) subjects with T2D who
were randomly assigned to placebo, 15 (57.7%) who were randomly
assigned to 7.5/46, and 39 (60.9%) were randomly assigned to
15/92 used metformin during the SEQUEL study. Therefore, to
assess effects of PHEN/TPM CR, changes in both cardiometabolic
disease variables and medication requirements were assessed.
Blood pressure
Both systolic and diastolic blood pressure decreased by 3–5
mm Hg at 108 wk compared with baseline in all treatment arms
(P , 0.0001 for all comparisons compared with baseline except
for placebo compared with baseline for systolic blood pressure,
P = 0.0002; NS for PHEN/TPM CR groups compared with
placebo; Figure 4A). Although the degree of blood pressure
reduction did not differ signiﬁcantly between treatment arms,
FIGURE 1. Trial proﬁle. Standardized lifestyle intervention was used across all treatment groups. Of the 27 subjects who discontinued the study drug
because of adverse events during the SEQUEL study, the event began during the CONQUER study for 3 subjects (one in each treatment group). For the
remaining 24 subjects, the adverse event leading to discontinuation of the study drug began during the SEQUEL study. *One subject in the 7.5/46 group
enrolled in the study but discontinued before receiving the study drug. 7.5/46, 7.5 mg phentermine/46 mg controlled-release topiramate; 15/92, 15 mg
phentermine/92 mg controlled-release topiramate.
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crease in the number of antihypertensive medications used,
whereas there was a net decrease in the number of medications
in subjects receiving 7.5/46 or 15/92 (Figure 4B). Speciﬁcally,
7.5% (n = 17) of subjects in the placebo group experienced
a decrease in concomitant antihypertensive medication use com-
p a r e dw i t h1 3 . 1 %( n = 20) in the 7.5/46 group and 15.6% (n =
46) in the 15/92 group. At the same time, more subjects re-
ceiving placebo experienced an increase in antihypertensive
medication use than did subjects treated with PHEN/TPM CR:
11.0% (n = 25), 9.2% (n = 14), and 5.8% (n = 17) for the pla-
cebo, 7.5/46, and 15/92 groups, respectively.
TABLE 1
Baseline data by treatment group
1
Standardized lifestyle intervention across all treatment groups
Entire cohort (CONQUER study) Long-term treatment (SEQUEL study)
Placebo
(n = 994)
PHEN/TPM CR
Placebo
(n = 227)
PHEN/TPM CR
7.5/46
(n = 498)
15/92
(n = 995)
7.5/46
(n = 153)
15/92
(n = 295)
Age (y) 51.2 6 10.3
2 51.1 6 10.4 51.0 6 10.7 52.7 6 9.8 52.2 6 10.6 51.2 6 10.4
Women [n (%)] 695 (69.9) 349 (70.1) 693 (69.6) 147 (64.8) 106 (69.3) 195 (66.1)
Race [n (%)]
White 861 (86.6) 429 (86.1) 850 (85.4) 198 (87.2) 134 (87.6) 244 (82.7)
African 114 (11.5) 56 (11.2) 122 (12.3) 28 (12.3) 17 (11.1) 44 (14.9)
Asian 6 (0.6) 5 (1.0) 11 (1.1) 0 1 (0.7) 5 (1.7)
American Indian or Alaskan native 4 (0.4) 6 (1.2) 8 (0.8) 2 (0.9) 1 (0.7) 0
Native Hawaiian or other Paciﬁc Islander 2 (0.2) 2 (0.4) 3 (0.3) 0 1 (0.7) 2 (0.7)
Other 12 (1.2) 5 (1.0) 8 (0.8) 1 (0.4) 0 3 (1.0)
Ethnicity [n (%)]
Hispanic or Latino 128 (12.9) 70 (14.1) 130 (13.1) 42 (18.5) 25 (16.3) 56 (19.0)
Not Hispanic or Latino 866 (87.1) 428 (85.9) 865 (86.9) 185 (81.5) 128 (83.7) 239 (81.0)
Weight (kg)
3 103.3 6 18.1 102.6 6 18.2 103.0 6 17.6 101.1 6 18.9 102.2 6 18.4 101.9 6 18.9
BMI (kg/m
2)
3 36.7 6 4.6 36.2 6 4.4 36.6 6 4.5 36.0 6 4.8 36.1 6 4.5 36.2 6 4.7
Waist circumference (cm)
3 113.4 6 12.2 112.6 6 12.5 113.2 6 12.2 113.0 6 12.5 112.9 6 12.3 112.2 6 12.3
Blood pressure (mm Hg)
3
Systolic 128.9 6 13.5 128.3 6 13.8 127.9 6 13.4 128.5 6 14.3 127.8 6 11.4 127.3 6 13.7
Diastolic 81.1 6 9.2 80.6 6 8.8 80.1 6 9.1 79.9 6 9.7 80.1 6 8.8 80.1 6 8.8
Heart rate (bpm)
3 72.1 6 9.9 72.1 6 10.1 72.6 6 10.1 70.6 6 10.5 72.0 6 9.6 73.0 6 10.3
Total cholesterol (mg/dL)
4 205.3 6 41.7 201.6 6 37.9 205.1 6 40.4 203.5 6 41.9 201.8 6 35.8 201.9 6 38.6
LDL cholesterol (mg/dL)
5 123.8 6 36.1 120.8 6 33.8 123.7 6 35.5 123.1 6 36.6 121.7 6 32.7 121.5 6 35.4
HDL cholesterol (mg/dL)
6 48.8 6 13.8 48.5 6 12.8 49.0 6 13.7 49.5 6 14.7 48.6 6 13.3 48.7 6 12.8
Triglycerides (mg/dL)
7 163.6 6 75.8 161.2 6 75.4 162.0 6 73.4 154.4 6 66.7 157.2 6 71.5 158.1 6 72.0
Fasting glucose (mg/dL)
8 106.5 6 23.5 105.8 6 20.7 105.9 6 21.6 109.3 6 24.4 110.7 6 25.3 108.2 6 24.1
Glycated hemoglobin (%)
9 5.9 6 0.8 5.8 6 0.7 5.9 6 0.8 6.0 6 0.9 6.0 6 0.9 6.0 6 0.8
Subjects with [n (%)]
Depression history 179 (18.0) 81 (16.3) 165 (16.6) 42 (18.5) 35 (22.9) 55 (18.6)
Hypertension
10 524 (52.7) 261 (52.4) 520 (52.3) 120 (52.9) 71 (46.4) 154 (52.2)
Hypertriglyceridemia
11 354 (35.6) 180 (36.1) 363 (36.5) 80 (35.2) 48 (31.4) 105 (35.6)
T2D
12 159 (16.0) 68 (13.7) 166 (16.7) 55 (24.2) 26 (17.0) 64 (21.7)
Metabolic syndrome 698 (70.2) 353 (70.9) 679 (68.2) 152 (67.0) 107 (69.9) 192 (65.1)
1 Baseline values for SEQUEL subjects were measured at the start of CONQUER. bpm, beats per minute; PHEN/TPM CR, controlled-release phentermine/
topiramate; T2D, type 2 diabetes; 7.5/46, 7.5 mg phentermine/46 mg controlled-release topiramate; 15/92, 15 mg phentermine/92 mg controlled-release topiramate.
2 Mean 6 SD (all such values).
3 Among CONQUER subjects, baseline weight, BMI, waist circumference, blood pressure, and heart rate values were missing for 2 subjects: one in the
placebo group and one in the 15/92 group.
4 Among CONQUER subjects at baseline, there were missing values for 2 subjects (one for placebo, one for 15/92).
5 Among CONQUER subjects at baseline, there were missing values for 7 subjects (4 for placebo, 3 for 15/92).
6 Among CONQUER subjects at baseline, there were missing values for 2 subjects (one for placebo, one for 15/92).
7 Among CONQUER subjects at baseline, there were missing values for 2 subjects (one for placebo, one for 15/92).
8 Among CONQUER subjects at baseline, there were missing values for 11 subjects (4 for placebo, 7 for 15/92).
9 Among CONQUER subjects at baseline, there were missing values for 9 subjects (5 for placebo, 4 for 15/92).
10 Subjects with hypertension were those with systolic blood pressure 140 and 160 mm Hg (130 and 160 mm Hg if diabetic) or diastolic blood
pressure 90 and 100 mm Hg (85 and 100 mm Hg if diabetic) or who were taking 2 antihypertensive medications and had blood pressure ,140/90
mm Hg.
11 Subjects with hypertriglyceridemia were those with fasting triglycerides between 200 and 400 mg/dL or who were taking 2 lipid-lowering
medications and had fasting triglycerides of ,200 mg/dL.
12 Subjects with diabetes were those with an established diagnosis of T2D, managed with lifestyle measures, metformin therapy, or both.
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Treatment with 7.5/46 and 15/92 led to progressively greater
reductions in triglycerides and greater increases in HDL cho-
lesterol than did placebo, despite the fact that the placebo group
required a markedly greater net increase in the number of lipid-
lowering medications used compared with the PHEN/TPM CR
groups. LDL cholesterol decreased in all treatment arms, with the
greatest reduction in the placebo group, whereas reduction in
non–HDLcholesterolwassimilarinallgroups(Figure4,CandD).
Similar to the changes seen in concomitant antihypertensive
medication use, more subjects receiving PHEN/TPM CR had a
decrease in lipid-lowering medications than did subjects re-
ceiving placebo: 3.1% (n = 7), 5.9% (n = 9), and 5.8% (n = 17)
for the placebo, 7.5/46, and 15/92 groups, respectively. Con-
versely, 20.3% (n = 46) of placebo-treated subjects increased
lipid-lowering medication use compared with 11.1% (n = 17) in
the 7.5/46 group and 10.5% (n = 31) in the 15/92 group.
Glycemic variables
PHEN/TPM CR treatment was associated with beneﬁcial
effects on glucose homeostasis at 108 wk (Table 2). When
compared with placebo, treatment with PHEN/TPM CR reduced
both fasting glucose and fasting insulin concentrations, which is
indicative of an improvement in insulin sensitivity (23). In
subjects without T2D at baseline, the favorable effects of weight
loss on insulin sensitivity and glycemia were associated with
decreased progression to T2D during the 2-y course of this
study. The annualized incidence rates for progression to T2D
FIGURE 2. Mean (95% CI) percentage weight loss from baseline to week 108. LS mean change in the overall study completer sample. Standardized
lifestyle intervention was used across all treatment groups. P , 0.0001 compared with placebo at all time points assessed. LOCF, last observation carried
forward; LS, least-squares; PHEN/TPM CR 7.5/46, 7.5 mg phentermine/46 mg controlled-release topiramate; PHEN/TPM CR 15/92, 15 mg phentermine/92
mg controlled-release topiramate.
FIGURE 3. Percentages (and 95% CIs) of subjects achieving 5%, 10%, 15%, or 20% weight loss from baseline to week 108 (ITT-LOCF).
Standardized lifestyle intervention was used across all treatment groups. *P , 0.0001 compared with placebo;
yP = 0.0072 compared with placebo. ITT,
intent-to-treat; LOCF, last observation carried forward; PHEN/TPM CR 7.5/46, 7.5 mg phentermine/46 mg controlled-release topiramate; PHEN/TPM CR
15/92, 15 mg phentermine/92 mg controlled-release topiramate.
302 GARVEY ET ALamong subjects without diabetes at baseline were 3.7%, 1.7%, and
0.9% in the placebo, 7.5/46, and 15/92 treatment groups, re-
spectively. These data indicate a 54% reduction in the progression
to T2D in subjects receiving 7.5/46 and a 76% reduction in
subjects taking 15/92 compared with placebo (Figure 5).
When only subjects with T2D at baseline were considered, the
initial mean Hb A1c at week 0 was similar in each of the 3
treatment groups (6.9% in subjects randomly assigned to pla-
cebo, 7.3% in the 7.5/46 treatment arm, and 6.9% in the 15/92
treatment arm). At 108 wk, Hb A1c did not substantially change
from baseline in the placebo group (0%), whereas treatment
with 7.5/46 and 15/92 led to reductions of 0.4% and 0.2%, re-
spectively (Figure 4E). In these actively managed subjects, these
reductions in Hb A1c were achieved without any net increase in
FIGURE 4. Effects of PHEN/TPM CR on cardiometabolic variables. LS mean changes (95% CI) in (A) blood pressure, (B) antihypertensive medications,
(C) lipid variables, (D) lipid-lowering medications, (E) Hb A1c, and (F) antidiabetic medications from baseline (week 0) to week 108 (ITT-LOCF). Changes in
Hb A1c represent the T2D subgroup. Changes in concomitant medications represent the safety study. Standardized lifestyle intervention was used across all
treatment groups. *Percentage increase minus percentage decrease; P , 0.05 for between-group differences.
yP , 0.01 compared with placebo;
zP , 0.0001
compared with placebo. Hb A1c, glycated hemoglobin; HDL-C, HDL cholesterol; ITT, intent-to-treat; LDL-C, LDL cholesterol; LOCF, last observation
carried forward; LS, least-squares; PHEN/TPM CR 7.5/46, 7.5 mg phentermine/46 mg controlled-release topiramate; PHEN/TPM CR 15/92, 15 mg
phentermine/92 mg controlled-release topiramate; T2D, type 2 diabetes.
2-y WEIGHT LOSS WITH PHENTERMINE/TOPIRAMATE CR 303antidiabetic medications in the 15/92 group [3.1% (n =9 )e x -
perienced a decrease and 3.1% (n = 9) experienced an increase]
and a small net increment in the 7.5/46 group [0.7% (n =1 )
decreased and 2.6% (n = 4) increased use] compared with larger
net increases in medications required in the placebo group [1.3%
(n = 3) decreased and 8.4% (n = 19) increased use; Figure 4F].
Analysis of all primary and secondary variables by using
multiple imputation instead of LOCF to accommodate for
dropoutyieldedresultsconsistentwiththosepresentedabove(see
Supplemental Tables 1 and 2 under “Supplemental data” in the
online issue). Similar results were also observed in the set of
subjects who completed the study while still taking the study
drug (see Supplemental Tables 3 and 4 under “Supplemental
data” in the online issue).
Safety and tolerability
AEs
PHEN/TPM CR was well tolerated over 108 wk, as shown by
the TEAEs (Table 3). The most commonly reported TEAEs
were upper respiratory tract infection, constipation, paraesthesia,
sinusitis, and dry mouth. The type of TEAEs occurring between
weeks 56 and 108 were similar to those reported in the overall
CONQUER sample from weeks 0 to 56 (17). However, as de-
lineated in Table 3, the incidence of individual TEAEs was
markedly lower in the second year (weeks 56–108) than in the
ﬁrst year (weeks 0–56). The incidence of SAEs from weeks 0 to
108 was 6.2% for placebo, 5.9% for 7.5/46, and 8.1% for 15/92.
The incidence of SAEs during the period of study extension
TABLE 2
Effects on glucose homeostasis at week 108 (ITT-LOCF)
1
Standardized lifestyle intervention across all treatment groups
PHEN/TPM CR
Placebo (n = 227) 7.5/46 (n = 153) 15/92 (n = 295)
Fasting glucose (mg/dL)
Baseline 109.3 6 24.37
2 110.7 6 25.28 108.2 6 24.05
LS change at 108 wk 3.7 (0.8, 6.5)
3 0.1 (23.4, 3.7) 21.2 (23.8, 1.4)
P value vs placebo N/A 0.0872 0.0048
Fasting insulin (lIU/mL)
Baseline 17.5 6 12.01 16.8 6 12.25 17.7 6 14.61
LS change at 108 wk 22.6 (23.9, 21.3) 25.3 (26.9, 23.7) 25.2 (26.4, 24.0)
P value vs placebo N/A 0.0051 0.0012
Hb A1c (%)
Baseline 6.0 6 0.90 6.0 6 0.90 6.0 6 0.85
LS change at 108 wk 0.2 (0.09, 0.2) 0.01 (20.08, 0.1) 0.00 (20.07, 0.07)
P value vs placebo N/A 0.0042 0.0003
1 Values represent changes from baseline (week 0) to week 108 (ITT-LOCF). Hb A1c, glycated hemoglobin; ITT,
intent-to-treat; LOCF, last observation carried forward; LS, least-squares; N/A, not available; PHEN/TPM CR, controlled-
release phentermine/topiramate; 7.5/46, 7.5 mg phentermine/46 mg controlled-release topiramate; 15/92, 15 mg phentermine/
92 mg controlled-release topiramate.
2 Mean 6 SD (all such values).
3 Mean; 95% CI in parentheses (all such values).
FIGURE 5. Annualized incidence rate for progression to T2D. Data represent subjects without T2D at baseline. Standardized lifestyle intervention was
used across all treatment groups. *P = 0.1514 compared with placebo;
yP = 0.0078 compared with placebo. PHEN/TPM CR 7.5/46, 7.5 mg phentermine/46
mg controlled-release topiramate; PHEN/TPM CR 15/92, 15 mg phentermine/92 mg controlled-release topiramate; T2D, type 2 diabetes.
304 GARVEY ET AL(weeks 56–108) was also similar across treatment groups: 4.0%,
2.6%, and 4.1% for placebo, 7.5/46, and 15/92, respectively—
none of which was reported by investigators to be related to
study treatment. The percentage of subjects discontinuing due to
AEs by week 108 was also similar across treatment groups:
3.1%, 4.5%, and 4.4% of subjects in the placebo, 7.5/46, and 15/
92 arms, respectively (Figure 1). There were no deaths in the
extension study. During SEQUEL, there were 2 pregnancies, one
carried to term in the 15/92 group and one resulting in mis-
carriage at ~6 wk gestation in the placebo group. The pregnancy
that was carried to full term resulted in a healthy macrosomic
infant with no observed teratogenic effects.
Physical examination and laboratory variables
Thereductionsinbloodpressureatweek108(Figure4A)were
accompanied by a mean increase in heart rate of 0.4 bpm in
placebo subjects, 1.3 bpm in 7.5/46 subjects, and 1.7 bpm in 15/92
subjects; there were no AEs reported that were relevant to
changes in heart rate, and there were no associated adverse
clinical sequelae. No dose-related changes were observed in shift
summaries of selected laboratory variables, and no subjects
experienced an SAE or discontinued the study drug due to
laboratory abnormalities. At week 108, there was a greater in-
crease in serum bicarbonate with placebo than with PHEN/TPM
CR. The mean changes in bicarbonate from baseline to week 108
were 2.2, 0.7, and 0.2 mEq/L for placebo, 7.5/46, and 15/92,
respectively (baseline mean bicarbonate concentration was 26.5
mEq/L in all 3 treatment groups). Although absolute changes
were small, more subjects treated with PHEN/TPM CR expe-
rienced a decrease from baseline in serum bicarbonate of .5
mEq/L at 2 consecutive visits during the 2-y study course than
did those in the placebo group; this was observed in 4 subjects
(1.8%) in the placebo-treated group, 20 (13.1%) in the 7.5/46-
treated group, and 48 (16.3%) in the 15/92-treated group over
108 wk. When looking only at weeks 56–108, 7 (4.6%) subjects
in the 7.5/46 group and 12 (4.1%) subjects in the 15/92 group
were observed to have a .5-mEq/L decrease in serum bi-
carbonate from baseline compared with 0 (0%) in the placebo
arm. The decreases in bicarbonate generally occurred during the
ﬁrst 3 mo of CONQUER, did not require clinical intervention,
and were not progressive during the 2-y study, tending to nor-
malize over time.
Psychiatric effects and suicidal behavior
There was no increase in serious suicidal ideation or suicidal
behavior based on the C-SSRS questionnaire during the 108 wk
of observation in subjects treated with PHEN/TPM CR. Six
subjects responded “yes” to the C-SSRS categories of suicidal
ideation and suicidality (3 placebo-treated subjects, 1 7.5/46-
treatedsubject,and215/92-treatedsubjects,butallwerebelowthe
threshold for “serious” as deﬁned by the instrument). Therewere 5
subjects with worsening suicidal ideation (2 in the placebo-, 1 in
TABLE 3
All adverse events with frequency of 5% in any PHEN/TPM CR group
1
Standardized lifestyle intervention across all treatment groups
Weeks 0–56 Weeks 56–108
PHEN/TPM CR
Placebo
(n = 227)
PHEN/TPM CR
Placebo
(n = 227)
7.5/46
(n = 153)
15/92
(n = 295)
7.5/46
(n = 153)
15/92
(n = 295)
n (%) n (%)
Constipation 16 (7.1) 25 (16.3) 62 (21.0) 7 (3.1) 11 (7.2) 12 (4.1)
Paraesthesia 6 (2.6) 21 (13.7) 62 (21.0) 0 (0.0) 1 (0.7) 10 (3.4)
Dry mouth 5 (2.2) 21 (13.7) 59 (20.0) 1 (0.4) 1 (0.7) 4 (1.4)
Upper respiratory tract infection 47 (20.7) 23 (15.0) 55 (18.6) 42 (18.5) 26 (17.0) 45 (15.3)
Nasopharyngitis 35 (15.4) 20 (13.1) 39 (13.2) 26 (11.5) 13 (8.5) 26 (8.8)
Dysgeusia 4 (1.8) 18 (11.8) 39 (13.2) 0 (0.0) 1 (0.7) 3 (1.0)
Sinusitis 19 (8.4) 17 (11.1) 39 (13.2) 18 (7.9) 12 (7.8) 28 (9.5)
Headache 21 (9.3) 8 (5.2) 28 (9.5) 6 (2.6) 4 (2.6) 12 (4.1)
Insomnia 15 (6.6) 12 (7.8) 24 (8.1) 8 (3.5) 9 (5.9) 11 (3.7)
Diarrhea 12 (5.3) 14 (9.2) 21 (7.1) 3 (1.3) 3 (2.0) 11 (3.7)
Back pain 19 (8.4) 11 (7.2) 21 (7.1) 7 (3.1) 9 (5.9) 15 (5.1)
Dizziness 6 (2.6) 9 (5.9) 20 (6.8) 2 (0.9) 2 (1.3) 1 (0.3)
Nausea 13 (5.7) 5 (3.3) 19 (6.4) 4 (1.8) 10 (6.5) 4 (1.4)
Bronchitis 8 (3.5) 9 (5.9) 17 (5.8) 7 (3.1) 8 (5.2) 10 (3.4)
Fatigue 11 (4.9) 7 (4.6) 17 (5.8) 2 (0.9) 2 (1.3) 4 (1.4)
Procedural pain 6 (2.6) 7 (4.6) 17 (5.8) 4 (1.8) 8 (5.2) 14 (4.7)
Arthralgia 20 (8.8) 13 (8.5) 13 (4.4) 14 (6.2) 7 (4.6) 16 (5.4)
Inﬂuenza 11 (4.9) 11 (7.2) 13 (4.4) 8 (3.5) 10 (6.5) 19 (6.4)
Urinary tract infection 11 (4.9) 8 (5.2) 13 (4.4) 13 (5.7) 14 (9.2) 18 (6.1)
Gastroenteritis 12 (5.3) 3 (2.0) 12 (4.1) 6 (2.6) 2 (1.3) 9 (3.1)
1 Preferred terms were deﬁned by the MedDRACoding Dictionary, version 10.1 (26). PHEN/TPM CR, controlled-release
phentermine/topiramate; 7.5/46, 7.5 mg phentermine/46 mg controlled-release topiramate; 15/92, 15 mg phentermine/92 mg
controlled-release topiramate.
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period, the incidence of reported anxiety-related AEs correlated
with increasing dose: 3.1%, 6.5%, and 9.5% for placebo, 7.5/46,
and 15/92 arms, respectively. Most anxiety events were mild in
severity. Three subjects in the 15/92 group experienced a severe
anxiety-related TEAE, with one subject discontinuing treatment.
There were no anxiety-related SAEs. The occurrence of de-
pression-related TEAEs was comparable in the placebo (7.9%)
and15/92(8.1%)groupsandoccurredatalowerrateinthe7.5/46
group (3.9%).
DISCUSSION
The previously published CONQUER study reported that
treatmentofoverweight andobese adultswith PHEN/TPMCR as
an adjunct to lifestyle intervention promoted weight loss and
reduced manifestations of cardiometabolic disease over 56 wk
when compared with lifestyle intervention plus placebo (17).
Thisextensionstudy,SEQUEL,maintainedtheblindedtreatment
groups for an additional 52 wk and showed that these beneﬁcial
therapeutic effects were sustained during a 2-y period.
After108wk,theadditionofPHEN/TPMCRtoastandardized
lifestyle modiﬁcation led to substantial weight loss that coincides
with theweight-loss target of 10% recommended by the National
Heart, Lung, and Blood Institute for overweight and obese
individuals (8). The percentage changes in body weight from
baselinewere –1.8%, –9.3%, and –10.5% in subjects treated with
placebo, 7.5/46, and 15/92, respectively (ITT-LOCF); and 10%
weight loss was achieved by .50% of PHEN/TPM CR–treated
subjects, whereas <12% of subjects receiving placebo met this
goal. Importantly, both doses of PHEN/TPM CR were signiﬁ-
cantly more effective than placebo regardless of baseline BMI
and were similarly effective at baseline BMI values extending
from ,30 to ,40. In those subjects with class III obesity (BMI
40), the 15/92 dose produced an even more pronounced degree
of weight loss, exceeding that observed with 7.5/46. These data
are indicative of therapeutic efﬁcacy for PHEN/TPM CR over
a wide range of initial BMI, although higher doses might be
more effective in cases of more severe obesity.
By design, subjects in the SEQUEL study were highly affected
by cardiometabolic disease, and many were treated with nu-
merous concomitant medications to control blood pressure, lipid
variables, and glycemic variables, which were actively managed
throughout the trial. PHEN/TPM CR improved these comor-
bidities and decreased the need for associated medications in
comparison with the placebo group. For example, after 2 y of
therapy, diastolic and systolic blood pressure showed equal
reductions in the placebo and PHEN/TPM CR groups; however,
this was accompanied by a net decrease in concomitant anti-
hypertensive medication use in PHEN/TPM CR treatment
groups, whereas antihypertensive medications were increased in
the placebo group. Reducing the need for medications used to
speciﬁcally control these comorbidities not only reduces the
medication burden associated with cardiometabolic disease but
could also improve subject compliance by decreasing their
medication regimen complexity and reducing the overall treat-
ment costs (24, 25).
When compared with placebo, PHEN/TPM CR–treated sub-
jects exhibited lower fasting glucose and fasting insulin values
compared with subjects receiving placebo, which is indicative of
an improvement in insulin sensitivity (23), and experienced
greater reductions in waist circumference, a measure of central
adiposity related to increased morbidity and mortality (21, 22,
27). Because insulin resistance and central adiposity are integral
to the development of cardiometabolic disease, it appears that
PHEN/TPM CR–induced weight loss is accompanied by fa-
vorable effects on pathophysiologic processes that could reduce
riskofmetabolicsyndrome,T2D,andCVD(8,21,22).Insupport
of this, we observed that, among subjects without T2D at
baseline, treatment with PHEN/TPM CR reduced progression to
T2Dby54%withthe7.5/46doseandby76%withthe15/92dose
when compared with the placebo intervention. Previous studies
have shown that lifestyle-intervention programs reduce pro-
gression to T2D among high-risk individuals with impaired
glucose tolerance, and the degree of protection correlated with
the amount of weight loss (28–31). Along these same lines,
incremental improvements in cardiometabolic disease risk fac-
tors have also been shown to correlate with an increasing degree
of weight loss, together with associated reductions in morbidity
and mortality (5, 32, 33).
Approximately 20% of subjects had T2D at study entry and
had been treated with lifestyle modiﬁcations alone, single-agent
metformin, or both. In the T2D subgroup, PHEN/TPM CR led to
signiﬁcant reductions in Hb A1c after 2 y compared with placebo.
Improvements in fasting glucose, fasting insulin, and Hb A1c
were experienced without any net change in concomitant anti-
diabetic medications in subjects with T2D who were randomly
assigned to 15/92 and a modest net increase in medications in
those assigned to 7.5/46, whereas the placebo group experienced
a substantial net increase in required antidiabetic medications to
achieve guideline-dictated goals. Thus, weight loss associated
with PHEN/TPM CR had a favorable impact on glycemic
control in the subjects with T2D, without a need for added oral
hypoglycemic agents.
Discontinuation rates during the extension study were similar
between placebo and PHEN/TPM CR–treated subjects. The type
ofAEsreportedduringweeks56–108intheextensionstudywere
similar to those in the ﬁrst 56 wk of the study; however, the
incidence rates were lower in the second year of the study. In
some subjects, PHEN/TPM CR treatment was associated with
reductions in serum bicarbonate, particularly in the ﬁrst 3 mo of
the study, which is likely a manifestation of the carbonic
anhydrase activity of topiramate. However, this effect was not
progressive in these subjects, and serum bicarbonate tended to
return toward normal during the remaining2yo ft h estudy
without the need for clinical intervention. PHEN/TPM CR
increased mean heart rate by 1.3–1.7 bpm over baseline; this
increase was not accompanied by any related AE reporting and
was accompanied by reductions in systolic and diastolic blood
pressure. Rigorous assessments of suicidality were conducted by
using the C-SSRS, which showed no increase in suicidal ideation
associated with PHEN/TPM CR and no difference from placebo
in AE reporting for incident depression. PHEN/TPM CR was
associated with a dose-dependent increase in the incidence of
anxiety.However,theseanxiety-relatedTEAEsweremostlymild
in nature and led to only one discontinuation of study drug.
Finally, during the 108-wk trial, there were 2 pregnancies, with
one pregnancy carried to term in a subject who was randomly
assigned to 15/92, resulting in a healthy infant without any
observed congenital malformations.
306 GARVEY ET ALLimitations of this study were that not all CONQUER subjects
were eligible to enroll into the SEQUEL extension because only
high-enrolling centers were used. Furthermore, participation in
the second-year extension study was optional. These aspects may
have resulted in bias toward the inclusion of subjects with
positive treatment outcomes, because one would expect that
subjects who achieved satisfactory weight loss would be more
likely to enroll for a second year. However, the baseline clinical
characteristics of the subgroup entering the SEQUEL study were
similar to those of the CONQUER cohort, with the exception of
a greater percentage of subjects with T2D in SEQUEL. Another
pointpertainsto thehigher rateofsubjects losttofollow-upin the
15/92 arm than in the placebo or 7.5/46 arms. Because the real
reason for study discontinuation in these subjects is not known,
this could result in an underestimation of important reasons for
patients dropping out, including AEs or lack of efﬁcacy. A third
limitation of this study is that hyperglycemia, high blood pres-
sure, and dyslipidemia were actively managed on the basis of
national treatment guidelines, resulting in the confounding im-
pact of medication changes on the secondary cardiometabolic
variables. Actual treatment effects may have been different if
related medications and doses were required to be ﬁxed, thereby
better isolating an effect of PHEN/TPM CR.
Medical options to promote sustained weight loss are limited.
The lipase inhibitor orlistat is currently the only approved
medication for chronic treatment of obesity in the United States
(10). Bariatric surgery is an option for long-term weight loss but
is generally limited to selected subjects with complicated or
severe obesity because of the inherent risks of invasive surgical
proceduresandtherequirementsforlong-termmedicalfollow-up
(9, 10, 34, 35). Results of this study suggest that PHEN/TPM CR
together with lifestyle measures may be an additional therapeutic
option for achieving long-term weight-loss in moderately to
severely obese subjects.
In conclusion, PHEN/TPM CR used as an adjunct to lifestyle
intervention for the treatment of obesity was well tolerated and
produced signiﬁcant, dose-related weight loss that was main-
tained during a 108-wk period. PHEN/TPM CR was also asso-
ciated with sustained improvements in the clinical manifestations
of weight-related cardiometabolic disease, including hypergly-
cemia, dyslipidemia, and elevated blood pressure, despite re-
duced use of concomitant medications. Importantly, these effects
of PHEN/TPM CR led to a reduction in the rate of progression to
T2D, with the greatest beneﬁts seen in subjects receiving PHEN/
TPM CR 15/92. Thus, PHEN/TPM CR may provide a well-
tolerated, effective, and sustainable treatment option for obese
subjects with cardiometabolic disease. Furthermore, the unmet
clinical need for effective weight-loss medications, together with
the favorable risk-beneﬁt proﬁle in the current study, suggests
that PHEN/TPM CR in conjunction with a lifestyle-intervention
program could be a valuable therapeutic approach to counteract
increasing rates of obesity and its related complications.
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